In head and neck squamous cell carcinoma, ANLN activates the ERK-MAPK pathway, thus upregulating PD-L1 level, which contributes to an immunosuppressive tumor environment [47]. This evidence concerns the gene ANLN and head and neck squamous cell carcinoma.